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PREAMBLE
Over the past decade, there has been an increasing
awareness that the quality of medical care delivered in the
United States is variable. In its seminal document dedicated
to characterizing deficiencies in delivering effective, timely,
safe, equitable, efficient, and patient-centered medical care,
the Institute of Medicine described a quality “chasm”.1
Recognition of the magnitude of the gap between the care
that is delivered and the care that ought to be provided has
stimulated interest in the development of measures of
quality of care and the use of such measures for the pur-
poses of quality improvement and accountability.
Consistent with this national focus on healthcare qual-
ity, the American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) have
taken a leadership role in developing measures of the qual-
ity of care for cardiovascular disease (CVD) in several
clinical areas (Table I.) The ACCF/AHA Task Force on
Performance Measures was formed in February 2000 and
was charged with identifying the clinical topics appropriate
for the development of performance measures and with
assembling writing committees composed of clinical and
methodological experts. When appropriate, these commit-
tees have included representation from other organizations
involved in the care of patients with the condition of focus.
The committees are informed about the methodology of
performance measure development and are instructed to
construct measures for use both prospectively and retro-
spectively, to rely upon easily documented clinical criteria,
and where appropriate, to incorporate administrative data.
The data elements required for the performance measures
SVN,
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to encourage uniform measurements of cardiovascular care.
The writing committees are also instructed to evaluate the
extent to which existing nationally recognized performance
measures conform to the attributes of performance mea-
sures described by the ACCF/AHA and to strive to create
measures aligned with acceptable existing measures when
this is feasible.
The initial measure sets published by the ACCF/AHA
focused primarily on processes of medical care, or actions
taken by healthcare providers, such as the prescription of a
medication for a condition. These process measures are
founded on the strongest recommendations contained in
the ACCF/AHA clinical practice guidelines, delineating
actions taken by clinicians in the care of patients, such as the
prescription of a particular drug for a specific condition.
Specifically, the writing committees consider as candidates
for measures those processes of care that are recommended
by the guidelines either as Class I, which identifies proce-
dures and/or treatments that should be administered, or
Class III, which identifies procedures and/or treatments
that should not be administered (Table II). Class II recom-
mendations are not considered as candidates for perfor-
mance measures. The methodology guiding the translation
of guideline recommendations into process measures has
been explicitly delineated by the ACCF/AHA, providing
guidance to the writing committees.10
Although they possess several strengths, processes of
care are limited as the sole measures of quality. Thus,
current ACCF/AHA Performance Measures writing com-
mittees are instructed to consider measures of structures of
care, outcomes, and efficiency as complements to process
measures. In developing such measures, the committees are
guided by methodology established by the ACCF/AHA.11
Table I. ACCF/AHA Performance Measure Sets
Topic
Original
Publication Date
Chronic heart failure2 2005 ACC/AHA
ACC/AHA
Chronic stable coronary artery
disease3
2005 ACC/AHA
Hypertension4 2005 ACC/AHA
ST-elevation and non–ST-elevation
myocardial infarction5
2006 ACC/AHA
Cardiac rehabilitation7 2007 AACVPR/
Atrial fibrillation8 2008 ACC/AHA
Primary prevention of
cardiovascular disease9
2009 ACCF/AH
Peripheral artery disease 2010* ACCF/AH
Percutaneous coronary
intervention
2011* ACCF/AH
AACVPR indicates American Association of Cardiovascular and Pulmonary
of Cardiology Foundation; ACR, American College of Radiology; AHA, A
PCPI, American Medical Association–Physician Consortium for Performanc
Society for Interventional Radiology; SVM, Society for Vascular Medicine;
*Planned publication date.Although implementation of measures of outcomes andefficiency is currently not as well established as that of
process measures, it is expected that such measures will
become more pervasive over time.
Although the focus of the performance measures writ-
ing committees is on measures intended for quality im-
provement efforts, other organizations may use these mea-
sures for external review or public reporting of provider
performance. Therefore, it is within the scope of the writing
committee’s task to comment, when appropriate, on the
strengths and limitations of such external reporting for a
particular CVD state or patient population. Thus, the met-
rics contained within this document are categorized as
either performance measures or test measures. Performance
measures are those metrics that the committee designates as
appropriate for use for both quality improvement and
external reporting. In contrast, test measures are those
appropriate for the purposes of quality improvement but
not for external reporting until further validation and test-
ing are performed.
All measures have limitations and pose challenges to
implementation that could result in unintended conse-
quences when used for accountability. The implementation
of measures for purposes other than quality improvement
requires field testing to address issues related but not lim-
ited to sample size, frequency of use of an intervention,
comparability, and audit requirements. The manner in
which these issues are addressed is dependent on several
factors, including the method of data collection, perfor-
mance attribution, baseline performance rates, incentives,
and public reporting methods. The ACCF/AHA encour-
ages those interested in implementing these measures for
purposes beyond quality improvement to work with the
ACCF/AHA to consider these complex issues in pilot
tnering Organizations Status
patient measures Currently undergoing update
PI—outpatient measures Currently undergoing update
PI Currently undergoing update
PI Currently undergoing update
Updated 20086
/AHA Updated 2010 (referral
measures only)7a
PI
CR/SCAI/SIR/SVM/SVN/SVS
AI/PCPI/NCQA Under development
ilitation; ACC, American College of Cardiology; ACCF, American College
an Heart Association; NCQA, National Committee for Quality Assurance;
rovement; SCAI, Society for Cardiac Angiography and Interventions; SIR,
Society for Vascular Nursing; and SVS, Society for Vascular Surgery.Par
—in
/PC
/PC
/PC
ACC
/PC
A
A/A
A/SC
Rehab
meric
e Impimplementation projects, to assess limitations and con-
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to enhance their utility for these additional purposes.
By facilitating measurements of cardiovascular
healthcare quality, ACCF/AHA performance measure-
ment sets may serve as vehicles to accelerate appropriate
translation of scientific evidence into clinical practice.
These documents are intended to provide practitioners
and institutions that deliver care with tools to measure
the quality of their care and identify opportunities for
improvement. It is our hope that application of these
performance measures will provide a mechanism through
which the quality of medical care can be measured and
improved.
Frederick A. Masoudi, MD, MSPH, FACC, FAHA
Table II. Applying Classification of Recommendations an
*Data available from clinical trials or registries about the usefulness/efficacy i
myocardial infarction, history of heart failure, and prior aspirin use. A recomm
is weak. Many important clinical questions addressed in the guidelines do no
there may be a very clear clinical consensus that a particular test or therapy is
IIa; Level of Evidence: A and B only), studies that support the use of compa
evaluated.Chair, ACCF/AHA Task Force on Performance Measures1. INTRODUCTION
The ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/
SVS Peripheral Artery Disease Performance Measures Writ-
ing Committee was charged to develop performance mea-
sures for peripheral artery disease (PAD). These
performance measures address lower extremity and abdom-
inal aortic disease, as covered by the ACC/AHA 2005
Guidelines for the Management of Patients With Peripheral
Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic) (hereafter, “PAD guidelines”).12 The
measures are intended for adults (age18 years) evaluated
in the outpatient setting. The writing committee acknowl-
edges that the field is rapidly evolving due to the contribu-
vel of Evidence
rent subpopulations, such as gender, age, history of diabetes, history of prior
tion with Level of Evidence B or C does not imply that the recommendation
themselves to clinical trials. Even though randomized trials are not available,
l or effective. †For comparative effectiveness recommendations (Class I and
erbs should involve direct comparisons of the treatments or strategies beingd Le
n diffe
enda
t lend
usefu
rator vtions of observational research, registries, and clinical trials.
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PAD will be necessary as the field advances. In addition,
there has been a recent change in the nomenclature for
vascular diseases.13 The term atherosclerotic vascular disease
refers to disease of the arteries (other than the coronary
arteries) caused by atherosclerosis.14 We have incorporated
this new terminology into this document where it is feasible
to do so.
1.1. Scope of the problem
The PAD guidelines12 state that:
the term “peripheral arterial disease” includes a diverse
group of disorders that lead to progressive stenosis or
occlusion, or aneurysmal dilation, of the aorta and its
noncoronary branch arteries, including the carotid, upper
extremity, visceral, and lower extremity arterial branches.
Peripheral arterial disease is the preferred clinical term that
should be used to denote stenotic, occlusive, and aneurys-
mal diseases of the aorta and its branch arteries, exclusive of
the coronary arteries (page e7).
For the purposes of these performance measures, the
term peripheral artery disease in the title is used to denote
atherosclerotic stenosis or occlusion of the aorta and arter-
ies supplying the lower extremities and ABDOMInal aortic
aneurysms (AAAs).13,14
PAD is a marker of systemic atherosclerosis. It has been
estimated that approximately 8 million persons in the
United States are afflicted with PAD.15 The prevalence of
PAD is approximately 12% of the adult population, with
men being affected slightly more than women.16,17 How-
ever, this percentage is age dependent. Almost 20% of
adults over the age of 70 years have PAD.18 Findings from
a national cross-sectional survey of PARTNERS (PAD
Awareness, Risk, and Treatment: New Resources for Sur-
vival) found that PAD afflicts 29% of patients who are age
70 years, age 50 to 69 years with at least a 10–pack-per-
year history of smoking, or age 50 to 69 years with a history
of diabetes.19 Despite the strikingly high prevalence of
PAD, this disease is underdiagnosed because it often pre-
sents with atypical symptoms or no ischemic symptoms
related to the legs at all. More than 70% of primary care
providers in the PARTNERS study whose patients were
screened were unaware of the presence of PAD in those
with the disease.19
The clinical presentation of PAD may vary from no symp-
toms to intermittent claudication, atypical leg pain, rest pain,
ischemic ulcers, or gangrene. Claudication is the typical symp-
tomatic expression of PAD. However, asymptomatic disease
may occur in up to 50% of all patients with PAD.12 The
Walking and Leg Circulation Study evaluated the symptoms
in patients with PAD. Of the 460 patients with PAD, 19.8%
had no exertional leg pain, 28.5% had atypical leg pain, 32.6%
had classic intermittent claudication, and 19.1% had pain at
rest.20 The results of these and other studies make it readily
apparent that more patients with PAD are asymptomatic or
have atypical leg symptoms than have classic intermittent
claudication.PAD has 2 major consequences: The first is a decrease
in overall well-being and quality of life due to claudication
and atypical leg pain.21–25 This often leads to patients
becoming sedentary and limiting the amount of walking
they do because of pain and discomfort. This may be
associated with depression.26 The second is a markedly
increased cardiovascular morbidity (myocardial infarction
and stroke) and mortality (cardiovascular and all-cause).
Treatment should be directed at each of these facets.
PAD is most often diagnosed by an ankle-brachial
index (ABI) 0.9. A low ABI is an independent predic-
tor of increased mortality.27–32 In the Framingham
Study, mortality in patients with intermittent claudica-
tion was 2–3 times higher than in age- and sex-matched
control patients, with 75% of PAD patients dying from
cardiovascular events. In a 15-year review of patients
with claudication, over 66% of mortality was attributable
to CVD.17 In a 10-year prospective study by Criqui et
al.,33 PAD patients both with and without a history of
CVD had significantly increased risk of dying from car-
diovascular and coronary heart disease compared with
age-matched control patients. The all-cause mortality
was 3.1 times greater and the CVD mortality was 5.9
times greater in patients with PAD compared with pa-
tients without PAD. The risk of cardiovascular events has
been found to be similar between PAD patients with
claudication and PAD patients without symptoms.34 The
extremely high morbidity and mortality in the PAD
population is due to myocardial infarction and
stroke.35,36 Both the Edinburgh Artery Study and the
ARIC (Atherosclerosis Risk in Communities) study cor-
related an increased risk of stroke and transient ischemic
attack with increased PAD severity.34,37 The combina-
tion of known coronary or cerebrovascular disease with
PAD has been shown to increase mortality risk. The
BARI (Bypass Angioplasty Revascularization Investiga-
tion) trial demonstrated that patients with multivessel
coronary artery disease (CAD) and PAD had a 4.9 times
greater relative risk of death compared with those indi-
viduals without PAD.38 In addition, in a pooled analysis
of 8 randomized prospective trials involving 19,867
patients undergoing percutaneous coronary interven-
tion, the 1-year mortality was 5% in patients with PAD
and coronary disease compared with 2.1% in patients
with coronary disease alone (P  0.001).39
Despite the overwhelming evidence that patients with
PAD are at a markedly increased risk of myocardial infarc-
tion, stroke, and death, these patients are often under-
treated, in that they do not receive antiplatelet therapy or
statins with the same frequency as do patients with coronary
artery disease.19
Thus, these PAD performance measures are directed at
strategies to improve diagnosis and treatment of patients
with PAD with an overall goal of improving patients’
walking distance and speed, improving their quality of life,
and decreasing cardiovascular event rates.
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 6 Olin et al 16211.2. Structure and membership of the writing
committee
The members of the writing committee included expe-
rienced clinicians and specialists in vascular medicine, car-
diology, vascular surgery, exercise physiology, vascular and
interventional radiology, interventional cardiology, endo-
crinology, and epidemiology. The writing committee also
included representatives from the American Association of
Cardiovascular and Pulmonary Rehabilitation (AACVPR);
the American College of Physicians (ACP); the American
College of Radiology (ACR); the American Diabetes Asso-
ciation (ADA); the National Heart, Lung, and Blood Insti-
tute (NHLBI); the PAD Coalition; the Society for Athero-
sclerosis Imaging and Prevention (SAIP); the Society for
Cardiac Angiography and Interventions (SCAI); the Soci-
ety of Cardiovascular Computed Tomography (SCCT);
the Society for Cardiovascular Magnetic Resonance
(SCMR); the Society for Interventional Radiology (SIR);
the Society for Vascular Medicine (SVM); the Society for
Vascular Nursing (SVN); and the Society for Vascular
Surgery (SVS).
1.3. Disclosure of relationships with industry
The work of the writing committee was supported
exclusively by the ACCF and AHA. Committee members
volunteered their time, and there was no commercial sup-
port for the development of these performance measures.
Meetings of the writing committee were confidential and
attended only by committee members and staff. Writing
committee members were required to disclose in writing all
financial relationships with industry relevant to this topic
according to standard ACCF and AHA reporting policies
and verbally acknowledged these relationships to the other
members at each meeting (see Appendix A). A confidential
final vote was conducted on each measure proposed for
inclusion in this set. Committee members with relation-
ships relevant to a specific measure did not participate in the
voting regarding that measure but were allowed to partic-
ipate in the discussion after disclosing the relationship. In
addition, Appendix B includes relevant relationships with
industry information for all peer reviewers of this docu-
ment.
1.4. Review and endorsement
Between July 20, 2009, and August 18, 2009, this
performance measure document underwent a 30-day pub-
lic comment period, during which ACCF and AHA mem-
bers and other health professionals had an opportunity to
review and comment on the text in advance of its final
approval and publication. Sixteen public responses were
received.
The official peer and content review of the document
was conducted simultaneously with the 30-day public com-
ment period, with 2 peer reviewers nominated by the
ACCF, 2 nominated by the AHA, and 2 peer reviewers
nominated by each of the other partnering organizations(ACR, SCAI, SIR, SVM, SVN, and SVS) and by each
collaborating organization (AACVPR, ADA, PAD Coali-
tion, SAIP, SCCT, and SCMR). Additional comments
were sought from clinical content experts and performance
measurement experts, and 8 individual content reviewer
responses were received. All peer and content reviewer
relationships with industry information was collected and
distributed to the writing committee and is published in
this document. (See Appendix B for details.)
The ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/
SVS 2010 Clinical Performance Measures for Adults With
Peripheral Artery Disease was adopted by the respective
Boards of Directors of the ACCF and AHA in August
2010. These measures will be reviewed for currency once
annually and updated as needed. They should be consid-
ered valid until either updated or rescinded by the ACCF/
AHA Task Force on Performance Measures.
2. METHODOLOGY
The development of performance systems involves
identification of a set of measures targeting a specific patient
population observed over a particular time period. To
achieve this goal, the ACCF/AHA Task Force on Perfor-
mance Measures has outlined 5 mandatory sequential steps.
Sections 2.1 through 2.5 outline how the writing commit-
tee addressed these elements.
2.1. Target population and care period
The target population consists of patients age 18
years. The writing committee developed exclusion criteria
specific to each measure to further specify the target popu-
lation.
2.2. Dimensions of care
Given the multiple potential domains of treatment
that can be measured, the writing committee identified
the relevant dimensions of care that should be evaluated.
We placed each potential performance measure into the
relevant dimension of care categories. Performance mea-
sures and test measures selected for inclusion in the final
set and their dimensions of care are summarized in Table
III. Appendix C provides the detailed specifications for
each measure.
Although the writing committee considered a number
of additional measures that focus on equally important
aspects of care, length and complexity considerations did
not allow their inclusion in the set. Some of the reasons for
this are discussed later in this paper.
2.3. Literature review
The writing committee used the PAD guidelines as the
primary source for deriving these measures.12 In addition,
the writing committee also reviewed guidelines in “Trans-
atlantic Inter-Societal Consensus for the Management of
Peripheral Arterial Disease (TASC II)”40 and the
“AACVPR/ACC/AHA 2007 Performance Measures on
terna
).
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diac Rehabilitation/Secondary Prevention Services”.7
2.4. Definition of potential measures
Explicit criteria exist for the development of perfor-
mance measures that accurately reflect quality of care.
These criteria include: 1) defining the numerators and
denominators of potential measures, and 2) evaluating
their applicability, interpretability, and feasibility. To select
measures for inclusion in the performance measurement
set, the writing committee prioritized the recommenda-
tions from the PAD guidelines.12
2.5. Selection of measures for inclusion in the
performance measure set
From analysis of these recommendations, the writing
committee identified potential measures relevant to adults
with PAD and then independently evaluated their potential
for use as performance measures using 9 exclusion criteria
adapted from the ACCF/AHA Attributes of Performance
Measures (Table IV) and the Performance Measure Survey
Form and Exclusion Criteria Definitions (Appendix D).
Member ratings of all the potential measures were collated
and discussed by the full committee so that members could
reach consensus about which measures should advance for
inclusion in the final measure set. There were 37 potential
measures initially advanced for full specification to assess
their suitability as performance measures. Through an iter-
ative process of repeated surveys within the writing com-
mittee, these potential measures were eventually reduced to
7 final performance measures and 2 test measures. After
additional discussion and refinement of measure specifica-
tions, the writing committee conducted a confidential vote
on whether to include each measure and whether to desig-
nate any of the measures as test measures in the final set.
Table III. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/
Dimension of Care Measures Matrix
Measure Name
Risk
Assessment Di
1. Ankle brachial index ✓
2. Cholesterol-lowering medications (statin)
3. Smoking cessation
4. Antiplatelet therapy
5. Supervised exercise
6. Lower extremity vein bypass graft surveillance
7. Monitoring of abdominal aortic aneurysms
T-1. Vascular review of systems for lower
extremity PAD*
✓
T-2. PAD “at risk” population pulse
examination*
✓
ACCF indicates American College of Cardiology Foundation; ACR, Amer
artery disease; SCAI, Society for Cardiac Angiography and Interventions; SIR
Society of Vascular Nursing; and SVS, Society for Vascular Surgery.
*Test measure (T-1 and T-2): This measure has been designated for use in in
(e.g., pay for performance, physician ranking, or public reporting programsWriting committee members were required to recuse them-selves from voting on any measures for which they had
significant relevant relationships with industry.
3. PERIPHERAL ARTERY DISEASE
PERFORMANCE MEASURES
3.1. Definition of peripheral artery disease and
abdominal aortic aneurysm
Atherosclerotic vascular disease encompasses a range
of noncoronary arterial syndromes that are caused by the
altered structure and function of the arteries that supply
the brain, visceral organs, and the limbs. Numerous
pathophysiologic processes can contribute to the cre-
ation of stenosis or aneurysms of the noncoronary arte-
Table IV. ACCF/AHA Attributes of Performance
Measures
Consideration Attribute
Useful in improving
patient outcomes
Evidence-based
Interpretable
Actionable
Measure design Denominator precisely defined
Numerator precisely defined
Validity type
● Face
● Content
● Construct
Reliability
Measure implementation Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collec-
tion
Overall assessment Overall assessment of measure for
inclusion in measurement set
Adapted from Normand et al.41.
PAD Performance Measurement Set:
stics
Patient
Education Treatment
Self-Management/
Compliance
Monitoring of
Disease Status
✓
✓ ✓ ✓
✓
✓ ✓ ✓ ✓
✓
✓
ollege of Radiology; AHA, American Heart Association; PAD, peripheral
iety of Interventional Radiology; SVM, Society for Vascular Medicine; SVN,
l quality improvement programs only. It is not appropriate for any other useSVS
agno
✓
✓
✓
✓
ican C
, Socrial circulation, but atherosclerosis remains the most
terna
).
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branch arteries.
3.2. Brief summary of the measurement set
Table V summarizes the ACCF/AHA/ACR/SCAI/
SIR/SVM/SVN/SVS PAD Performance Measurement
Set—those measures with the highest level of evidence and
support among the writing committee members. Appendix
C provides the detailed specifications for each performance
measure, including the numerator, denominator, period of
assessment, method of reporting, sources of data, rationale,
clinical recommendations, recommended level of attribu-
tion and/or aggregation, and challenges to implementa-
tion.
3.3. Data collection
These performance measures for PAD are ideally in-
tended for prospective use to enhance the quality improve-
ment process but may also be applied retrospectively. We
recommend use of a data collection instrument to aid
Table V. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/S
Measure Name
Performance Measures
1. ABI Measuremen
for PAD
2. Cholesterol-Lowering Medications
(Statin)
Drug therap
lipoprotein
with PAD
3. Smoking Cessation Smoking-ces
active smo
4. Antiplatelet Therapy Antiplatelet
of myocard
vascular de
history of s
5. Supervised Exercise Supervised e
patients wi
claudicatio
6. Lower Extremity Vein Bypass Graft
Surveillance
ABI and Du
extremity v
7. Monitoring of Abdominal Aortic
Aneurysms
Monitoring
abdominal
between 4
Test Measures
T-1. Vascular Review of Systems for
Lower Extremity PAD*
Medical or p
impairmen
ischemic re
wounds
in patients
PAD
T-2. PAD “At Risk” Population Pulse
Examination*
Measuremen
extremities
at risk for P
ABI indicates ankle brachial index; ACCF, American College of Cardiolo
Association; PAD, peripheral arterial disease; SCAI, Society for Cardiac A
Society for Vascular Medicine; SVN, Society of Vascular Nursing; and SVS,
*Test measure (T-1 and T-2): This measure has been designated for use in in
(e.g., pay for performance, physician ranking, or public reporting programscompilation (see Appendix E). Individual institutions maymodify the sample instrument or develop a different tool
based on local practice and standards.
3.4. Exclusion criteria and challenges to
implementation
The writing committee added exclusion criteria, recog-
nizing that there are justifiable reasons for not meeting the
performance measures. These reasons should be recorded
on the data collection form. Documentation of such factors
should be encouraged because this will provide data for
future research and facilitate in-depth quality improvement
in situations in which there are apparent outliers with
respect to the number of patients with medical or patient-
centered reasons for exclusion.
Challenges to implementation of the measures are dis-
cussed, where applicable. In general, the initial challenge
facing any measurement effort is inadequate documenta-
tion. Discussion of these challenges is not an argument
against any individual measure. Rather, it is a cautionary
note that draws attention to areas where additional research
AD Performance Measurement Set
ription Attribution
BI in patients at risk All clinicians managing patients with
cardiovascular disease
lowering low-density
esterol in patients
All primary care and cardiovascular
medicine physicians
intervention for
in patients with PAD
All clinicians managing patients with
cardiovascular disease
y to reduce the risk
farction, stroke, or
patients with a
omatic PAD
All clinicians managing patients with
cardiovascular disease
e training for
ermittent
All clinicians managing patients with
cardiovascular disease
ltrasound of lower
ypass site
Vascular specialists only
mptomatic
c aneurysms
5.4 cm in diameter
All clinicians managing patients with
cardiovascular disease
al history of walking
udication or
in, and nonhealing
k for lower extremity
All clinicians managing patients with
cardiovascular disease
ulses in the lower
tients
All clinicians managing patients with
cardiovascular disease
undation; ACR, American College of Radiology; AHA, American Heart
raphy and Interventions; SIR, Society of Interventional Radiology; SVM,
ty for Vascular Surgery.
l quality improvement programs only. It is not appropriate for any other useVS P
Desc
t of A
y for
chol
sation
king
therap
ial in
ath in
ympt
xercis
th int
n
plex u
ein b
of asy
aorti
.0 and
erson
t, cla
st pa
at ris
t of p
in pa
AD
gy Fo
ngiog
Sociemay enhance the value of the measures.
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The performance measures that were chosen fulfilled
the criteria, as outlined in Table IV:
1. They are useful in improving patient outcomes and are
based on Class I evidence: interpretable and actionable.
2. The measure design is precisely defined and valid in face,
content, and construct.
3. The measure can be implemented with reasonable effort
and cost and in a reasonable time period.
The writing committee examined all Class I and Class
III recommendations from the PAD guidelines and consid-
ered only those guideline recommendations that could be
translated into measures that met the criteria stated above.
Many potential performance measures did not meet these 3
criteria and thus were not included in this set of measures.
Reasons for some of these omissions are discussed in sec-
tion 4.7. In summary, the final selection of performance
measures was based on the evidence base for a given mea-
sure, the ease and/or complexity of measurement, and
whether the measurement was covered in previously pub-
lished measurement sets.
Assessment of care remains challenging in all areas of
medicine but is particularly so in patients with PAD. PAD is
underdiagnosed, undertreated, and poorly understood by
many practicing clinicians.19 Although the PAD guide-
lines12 provide a good first step for many clinicians to
establish their clinical expertise, continuing research upon
which to base future measurement is important, and con-
tinuing modification of the guidelines will be necessary to
keep up to date with current knowledge and improve
patient outcomes.
Potential performance measures for which the chal-
lenges to implementation were considered too difficult to
overcome were not included in this data set. In general, the
requirements for documentation are an important chal-
lenge of any measurement effort. The acknowledgment of
these challenges is not an argument against measurement.
They are listed to make the reader aware of the potential
obstacles that may occur in any measurement set.
4.1. Attribution and/or aggregation
Clinical performance measures are used to assess quality
of care provided by individual physicians. Hence, caution
must be exercised if several physicians are actively involved
at once with a particular episode of care. Given the nature
and clinical course of PAD, most patients require longitu-
dinal follow-up by physicians of different specialties. It is
likely that the ACCF/AHA/ACR/SCAI/SIR/SVM/
SVN/SVS 2010 Performance Measures for Adults With
Peripheral Artery Disease will be utilized by the Centers for
Medicare and Medicaid Services and other third-party pay-
ers to assess each individual physician caring for patients
with PAD. Therefore, it is critical that physicians effectively
document in the patient’s medical records all clinical data
necessary for each PAD performance measure. More im-
portant is the need for all clinicians who are participating ina patient’s care to share this information consistently so that
data collection for performance measures attributable to all
involved can be readily available. Such information sharing
will also improve communication and coordination of care
among physicians caring for patients with PAD.
For the first time in an ACCF/AHA performance mea-
sure set, attribution and/or aggregation is listed in each
measure. Attribution indicates which clinicians and/or
practices should report a given measure (i.e., all clinicians
and/or practices managing patients with CVD versus only
vascular specialists). The level of “aggregation” (clinician
versus practice) will depend upon the availability of ade-
quate sample sizes to provide stable estimates of perfor-
mance. Healthcare providers from many different special-
ties (primary care, internal medicine, cardiovascular
medicine, vascular medicine, interventional radiology, vas-
cular surgery, and endocrinology) may care for patients
with PAD, yet not all specialists should be responsible for
each performance measure. For example, for lower extrem-
ity bypass graft surveillance (Performance Measure 6) only
vascular specialists should be held accountable. In addition,
the writing committee believes it is now beyond the scope
of practice to expect vascular surgeons and interventional
radiologists to manage cholesterol-lowering medications
(Performance Measure 2). However, vascular surgeons and
interventional radiologists should communicate with the
primary care physician about the use of statin and antiplate-
let therapy in patients with PAD and document such com-
munication and medication use in the chart.
4.2. Overlap with existing national performance
measure sets
All individuals with PAD, regardless of symptom status,
ABI, or efficacy of revascularization, face as high (or higher)
a short-term risk of a morbid or mortal ischemic event
(myocardial infarction, stroke, or death) as that suffered by
patients with any other CVD12,42 Nevertheless, although
the published peer-reviewed evidence base—as docu-
mented in the PAD guidelines12—unambiguously docu-
ments that impressive risk reductions are achieved by use of
proven pharmacological and lifestyle interventions, individ-
uals with PAD in clinical practice are known to less consis-
tently receive these treatments.19,43–45 Furthermore, phy-
sicians often do not recognize the cardiovascular risk of
PAD. This is a major reason that they do not consistently
prescribe such risk-reduction medications for patients with
PAD, as they do for individuals with coronary artery dis-
ease.46,47 These facts are evident even though other cardio-
vascular treatment guidelines for lipid lowering, hyperten-
sion, and smoking have long included PAD as a “very high
risk” patient cohort.
These PAD performance measures therefore provide a
critical disease-based opportunity to improve PAD clinical
care and outcomes, which can be accomplished only if the
use of risk-reduction interventions are measured (as they
have been for acute coronary syndromes and heart failure)
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ically achieved.
One measure would evaluate use of statin therapy for
lowering lipoprotein cholesterol (LDL-C) in patients with
PAD by measuring the fraction of eligible patients with
PAD who were prescribed a statin and whose LDL-C is
100 mg/dL. The second measure would evaluate the use
of smoking-cessation interventions for active smoking in
patients with PAD by documenting the fraction of patients
with PAD identified as current smokers who have received
smoking-cessation intervention. The third measure would
evaluate use of antiplatelet therapy to reduce the risk of
myocardial infarction, stroke, or cardiovascular death in
patients with a history of symptomatic PAD. Each of these
measures should be achievable by any physician, advanced
practice nurse, practice, or healthcare system that is dedi-
cated to improving health outcomes for individuals with
PAD.
4.3. Ankle brachial index
Individuals with PAD are at significant risk for cardio-
vascular ischemic events, including myocardial infarction,
stroke, and death .12,48 Epidemiological studies have
shown that even asymptomatic patients suffer mortality
rates significantly higher than individuals who do not have
PAD. PAD can easily be diagnosed with an ABI
0.90.12,27,29,32,33,35 The ABI is measured with a hand-
held continuous wave Doppler ultrasound device and a
blood pressure cuff. The higher systolic pressure measured
from either the posterior tibial or dorsalis pedis artery (in
each leg) is compared with the higher brachial artery pres-
sure taken from either arm. Diagnosis of PAD provides the
physician the opportunity to initiate treatment to reduce
cardiovascular risk and therefore decrease morbidity and
mortality. This is particularly important for those individu-
als who have not previously been diagnosed with an ath-
erosclerotic disease.
The ABI is a simple, inexpensive, noninvasive test that
can be easily performed in most clinical settings and has a
sensitivity of 79% to 95% and a specificity of 95% to 100%.12
Numerous studies have demonstrated that an abnormal
ABI correlates with a significantly increased risk of coronary
heart disease, stroke, and cardiovascular death. Most re-
cently, a 2008 meta-analysis demonstrated that a low ABI
(0.90) was associated with approximately twice the 10-
year total mortality, cardiovascular mortality, and major
coronary event rate compared with the overall rate in each
Framingham Risk Score category. Including the ABI in
cardiovascular risk stratification using the Framingham Risk
Score would result in reclassification of the risk category
and modification of treatment recommendations in ap-
proximately 19% of men and 36% of women.49 The writing
committee recognizes that reimbursement for the ABI in
the office setting is incomplete and that requiring an ABI in
persons at risk for PAD adds a burden to busy primary care
clinicians. Despite this, the weight of the evidence of the
utility of the ABI to predict cardiovascular morbidity andmortality and all-cause mortality and to facilitate initiation
of treatment to reduce cardiovascular events has led this
writing committee to support the measurement of the ABI
in patients at risk (see Performance Measure 1 for definition
of at risk) for PAD. It is the writing committee’s belief that
this measure will also be useful in better documenting
current practice patterns of physician office evaluation and
in identifying potential opportunities for quality improve-
ments for patients with PAD.
4.4. Antiplatelet therapy
In the PAD guidelines12 and the “Inter-Society Con-
sensus for the Management of Peripheral Arterial Disease
(TASC II)”,40 antiplatelet therapy is recommended for the
treatment of patients with PAD. Several documents in the
past year have questioned the efficacy of aspirin in patients
with asymptomatic PAD.50,51 The role of antiplatelet ther-
apy in asymptomatic patients is addressed in the upcoming
ACCF/AHA focused update to the 2005 PAD guidelines;
thus, we have included only patients with a history of
symptomatic PAD in this performance measure.
4.5. Supervised exercise
The PAD guidelines recommend supervised exercise to
treat patients with PAD who have claudication because of
its proven efficacy and safety.12 Any performance measure
that is intended to measure the “appropriateness” of care
offered to individuals with PAD and claudication would
rightly measure the applied use of this treatment care
standard.
Nevertheless, the writing committee is aware that, as
for many performance measures, real-world barriers exist
that limit actual use of a treatment. The efficacy and safety
of PAD exercise rehabilitation for the treatment of claudi-
cation is a uniformly recommended, evidence-based, con-
sensus-driven therapy that has a Class I (Level of Evidence:
A) recommendation in the 2005 PAD guidelines (12).
There is currently incomplete reimbursement for, and
therefore a lack of broad availability of, supervised exercise
programs, which makes this PAD performance measure
difficult to carry out. However, the data supporting the
ability of supervised exercise to increase walking capability
in patients with claudication are so strong52 that we feel
including this treatment modality as a performance mea-
sure may help to move it into more general use. Another
limiting factor for the low use of exercise rehabilitation is
the lack of counseling about and prescription of this ther-
apy by many healthcare professionals. The writing commit-
tee believes that more patients would choose a trial of
exercise, as they do in other rehabilitative therapies (e.g.,
cardiac rehabilitation, pulmonary rehabilitation, and ortho-
pedic rehabilitation), if they were made aware that this is an
efficacious treatment option, or if they were prescribed this
option, and especially if it were carried out in a supervised
setting.
Patients with PAD should be counseled about all of
their treatment options in order to engage them fully in
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seling and discussion of treatment options should in-
clude use of supervised exercise, pharmacological man-
agement, and/or the various percutaneous or open
surgical revascularization techniques. Inasmuch as exer-
cise rehabilitation has not to date been routinely recom-
mended by clinicians, it is impossible to define what
percentage of patients would choose supervised exercise
as the first-line therapy if they were made aware of this
option and if this treatment modality were reimbursed by
third-party payers. Thus, the inclusion of supervised
exercise in the PAD performance measures will assure the
following: 1) that this evidence-based therapeutic mo-
dality will be provided as a component of informed
decision making about the various treatment strategies
for patients with PAD; 2) that data can be collected to
evaluate current claudication treatment recommenda-
tion practice patterns; and 3) that these data will be able
to be tracked over time as PAD rehabilitation programs,
and possible insurance reimbursement, become more
widely available. A variety of supervised exercise proto-
cols have been published.53 Practices should create indi-
vidual options for patients that mirror these protocols in
physiologic effectiveness.
It should be noted that ongoing advocacy efforts are
under way to align future Centers for Medicare and Med-
icaid Services and other health payer reimbursement to the
current PAD guideline evidence base and thus to include
reimbursement for PAD exercise rehabilitation programs.
It is anticipated that this essential performance measure will
permit patients, healthcare providers, and health payers to
be able to make incremental improvements that will assure
patient access to all proven claudication therapies. Most
current cardiac rehabilitation programs, which are broadly
available, are poised to provide PAD exercise rehabilitation.
This performance measure provides data that can help
translate evidence-based PAD knowledge into real-world
care improvements.
4.6. Test measures
Although it is common sense that one should obtain an
accurate vascular history and perform a good vascular exami-
nation in all patients suspected of having PAD, the writing
committee chose to include measures T-1 and T-2 as test
measures only. This decision was made because of the desire
to limit the number of performance measures to a reasonable
number. We also believe that these measures would be diffi-
cult and time consuming to track and would require addi-
tional resources for monitoring that may not be available. As
test measures, their use should be for internal quality improve-
ment programs only. They are not appropriate for other uses,
such as pay for performance, physician ranking, or public
reporting programs.
4.7. Potential measures considered but not included
in this set4.7.1. Lower extremity endovascular revascular-ization surveillance. Although there has been some con-
troversy in the literature there have been several good
studies (Class I, Level of Evidence: A) demonstrating that
surveillance for vein bypass is an effective way to preserve
the long-term function of the bypass and to identify and
correct problems before the bypass thromboses.54–56
There are no such studies available in patients who have
undergone endovascular revascularization, yet it makes in-
tuitive sense that if a problem (e.g., restenosis) can be
identified, the problem may be correctable before the artery
occludes. However, the PAD guidelines gave this a Class
IIa designation, thus we were unable to include this as a
performance or test measure.
4.7.2. Chronic critical limb ischemia and acute
limb ischemia. The writing committee considered nu-
merous potential measures that would focus on the surgical
as well as endovascular management of patients with
chronic and acute limb ischemia. Although the manage-
ment of chronic and acute limb ischemia is considered
extremely important by the writing committee, specific
measures were not included in this area for a variety of
reasons. One of the important reasons is that the goal of the
writing committee was to develop performance measures
that would be relevant to as many clinicians and as many
patients as possible. Patients with chronic limb ischemia
and acute limb ischemia needing surgical or endovascular
therapy represent a small minority of all patients with PAD.
Furthermore, the clinicians who actively manage these
problems represent a small subset of clinicians who manage
patients with PAD. As such, the writing committee felt that
the scope of any performance measures adopted in these
areas would not be relevant to enough patients and clini-
cians to justify their inclusion.
Another reason for not including measures in these
areas is the complexity of any metrics that might be devel-
oped to measure the performance of care. These patients
present with very complex symptoms, with multiple comor-
bidities and significant anatomic variations, which render
simple metrics impractical. Finally, the level of evidence for
establishing specific guidelines and measures in these areas
is not sufficiently rigorous to justify specific performance
measures for the management of chronic or acute limb
ischemia.
4.7.3. Renal and mesenteric artery disease. There
are no performance measures related to renal or mesenteric
artery disease included in this report. While renal artery
disease is a common cardiovascular condition, the PAD
guidelines contain no Class I recommendations related to
this disease, and no randomized controlled trials of suffi-
ciently high caliber exist to guide clinicians in the optimal
management of patients with renal artery disease. In addi-
tion, a considerable controversy remains among “experts”
as to the most effective therapy to manage this group of
patients. Until the results of the CORAL (Cardiovascular
Outcomes in Renal Atherosclerotic Lesions) trial57 are
reported, healthcare providers will continue to manage this
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available literature.
Likewise, there is even less scientific information on
mesenteric artery disease available, and thus no perfor-
mance measures were deemed appropriate for this topic.
4.7.4. Exercise treadmill testing. Exercise treadmill
testing can assist clinicians in the evaluation of the func-
tional status of PAD patients. A decrease in the postexercise
ankle pressures can confirm a diagnosis of PAD in symp-
tomatic patients who have a normal ABI at rest. In addi-
tion, exercise treadmill testing allows quantification of a
patient’s baseline and/or postprocedure functional limita-
tion or improvement.
Despite the potential benefits of this procedure, the
writing committee agreed both that this measure would be
difficult to implement and that there were other measures
with higher priority; thus, we decided not to include this
measure.
4.7.5. Computed tomographic angiography and
magnetic resonance angiography. It has been clearly
shown that computed tomographic angiography and mag-
netic resonance angiography are useful imaging strategies
to delineate the anatomy and help plan percutaneous and
surgical revascularization.12 However, this potential per-
formance measure did not meet the criteria for a good
performance measures as outlined in Table IV.
4.7.6. Management of hypertension and diabe-
tes. It is very important to control blood pressure and
diabetes to goal levels in patients with PAD. Excellent
performance measures already exist on the diagnosis and
management of hypertension and diabetes mellitus, and the
reader is referred to those.4,58,59
4.7.7. Screening for abdominal aortic aneu-
rysm This was the most difficult measure to exclude.
However, the PAD guidelines assigned this only a Class IIa
designation. Because only Class I designations are consid-
ered for performance measures, screening for abdominal
aortic aneurysm was excluded. However, the U.S. Preven-
tive Task Force60 and the Societies for Vascular Medicine
and Surgery61 recommend screening for AAA in the fol-
lowing patient populations:
● Men age60 years with a history of AAA in a parent or
sibling.
● Men age 65 to 75 years who have ever smoked 100
cigarettes in their lifetime.
Screening this patient population has been shown to
decrease aneurysm-related mortality.61–64 A meta-analysis
of 4 large randomized prospective controlled trials65 eval-
uated the midterm (3.5 to 5 years) and long-term (7 to 15
years) results as related to aneurysm-related mortality and
total mortality. Heterogeneity between the studies was
assessed by the chi-square test. In cases of heterogeneity,
random effect models were used. The pooled midterm
analysis demonstrated a reduction in AAA-related mortality
(odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.44to 0.72). Overall mortality was nonsignificantly reduced
(OR 0.94, 95% CI, 0.86 to 1.02). The long-term results
also showed a reduction in AAA-related mortality (OR:
0.47, 95% CI: 0.25 to 0.90) and a significant reduction in
overall mortality (OR: 0.94, 95% CI: 0.92 to 0.97). The
conclusion of this meta-analysis was that population screen-
ing for AAA reduces AAA-related and overall mortality but
local differences may influence the cost-effectiveness of
screening.
Kim and associates66 showed that the benefit derived at
4 years was maintained at 7 years of follow-up, with a
relative risk reduction of aneurysm-related death of 47%.
They also showed that there is a substantial cost-benefit to
screening, which is estimated on the basis of AAA-related
mortality as U.S. $19,500 per life-year gained. The mortal-
ity curves diverge at a constant rate after 1 year, and the area
between the curves is greater at years 5 to 7 than years 1 to
4. Thus, the cost per life-year gained decreases in the later
years.67 Therefore, when the PAD guideline is revised, if
screening for AAA becomes a Class I recommendation,
creation of an associated performance measure will be
considered.
4.7.8. Outcome measures. The writing committee
recognizes that the most interpretable and potentially im-
portant performance measures are outcome measures;
however, there are a number of significant limitations to
their use for provider accountability or public reporting.11
Outcome measures are therefore currently best suited for
use as tools to assist providers in understanding their own
performance.
Krumholz et al.6 have eloquently described the impor-
tance of assessing outcomes in addition to measuring per-
formance on key processes of care, per se:
Although measures focusing on processes of care have
substantial appeal as a means of reflecting quality, such
measures assess only a small proportion of all of the care
delivered and apply to only subsets of the population with a
particular condition. Furthermore, while determining
whether a particular process of care was delivered, such
measures do not convey information on the effectiveness of
the process. Finally, although patients presumably care
about the processes of care that they receive, this interest
reflects an assumption that better processes of care ulti-
mately result in better outcomes. For these reasons, out-
comes measures have been proposed as a means of comple-
menting process measurement as a reflection of quality (p.
2054).
A recent multidisciplinary AHA Scientific Statement,
which is endorsed by the ACCF, identified 7 attributes of
outcomes measures suitable for public reporting.11 These
attributes include: 1) a clear and explicit definition of an
appropriate patient sample; 2) clinical coherence of model
adjustment variables; 3) sufficiently high-quality and timely
data; 4) designation of an appropriate reference time before
which covariates are derived and after which outcomes are
measured; 5) use of an appropriate outcome and a stan-
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an analytical approach that takes into account the multilevel
organization of data; and 7) disclosure of the methods used
to compare outcomes, including disclosure of performance
of risk-adjustment methodology in derivation and valida-
tion samples.
While the writing committee recognizes the impor-
tance of developing scientifically valid, effective, and useful
measures of clinical outcomes for PAD, we are not yet at the
point to do so with the data available. Outcome measure-
ments, however, should be considered in future revisions of
the PAD performance measures.
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Peripheral Artery Disease Performance Measurement Set Specifications
1. ABI
Measurement of ABI in patients at risk for PAD
Numerator Patients in whom measurement and numerical results of an ABI* are documented at least once in the
last 5 y.
Denominator All patients:
 Age 18 y with walking impairment or claudication or lower extremity nonhealing wounds OR
 Age 50–69 y with a history of smoking or diabetes OR
 Age 70 y
Exceptions:
 Patients with known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery
disease).
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not
performing an ABI (e.g., amputation or limited life expectancy).
Period of Assessment 5-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
The ABI is a very specific and sensitive measure for the detection of PAD. It can be performed in the office setting and predicts
morbidity and mortality. PAD is considered a CHD risk equivalent, and documentation of PAD changes the management of risk
factors such as hypertension and dyslipidemia.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Individuals with asymptomatic lower extremity PAD should be identified by examination and/or measurement of the ABI so that
therapeutic interventions known to diminish their increased risk of myocardial infarction, stroke, and death may be offered. (Level of
Evidence: B)
The resting ABI should be used to establish the lower extremity PAD diagnosis in patients with suspected lower extremity PAD,
defined as individuals with exertional leg symptoms, with nonhealing wounds, who are 70 years or older or who are 50 years or older
with a history of smoking or diabetes. (Level of Evidence: C)
TASC-II40
Recommendation 12
Recommendations for ABI screening to detect peripheral arterial disease in the individual patient.
An ABI should be measured in:
● All patients who have exertional leg symptoms [B].
● All patients age 50 to 69 y and who have a cardiovascular risk factor (particularly diabetes or smoking) [B].
● All patients age 70 y regardless of risk factor status [B].
● All patients with a Framingham Risk Score 10%–20% [C].
Attribution/Aggregation
This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether an ABI was performed at least once in the last 5 y.
Per patient population:
Percentage of patients for whom ABI was performed at least once in the last 5 y.
Challenges to Implementation
 Lack of uniform reimbursement for ABI performed according to evidence-based guidelines.
 Lack of equipment to perform this measurement in the physician’s office.
 Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
ABI indicates ankle-brachial index; CHD, coronary heart disease; and PAD, peripheral artery disease.
*ABI is the ratio of the systolic ankle arterial pressure to the systolic brachial arterial pressure. The higher of the brachial pressures is used as the denominator
for both right and left ratios, and the higher of the 2 ankle pressures (posterior tibial or dorsalis pedis) is used as the numerator for each leg.
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Drug therapy for lowering LDL-C in patients with PAD
Numerator Patients who
 Were prescribed a statin and whose LDL-C is 100 mg/dL OR
 Were prescribed a statin at maximal dose* OR
 Whose LDL-C is 100 mg/dL without a statin OR
 Whose LDL-C 100 mg/dL and who had a medical or patient reason that a statin at maximal
dose* was not prescribed documented by a physician, advanced practice nurse, or physician
assistant.
Denominator All patients age 18 y with PAD.
PAD is defined as the presence of 1 or more of the following:
 Claudication
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
 Amputation for critical limb ischemia
 Abnormal noninvasive test (e.g., ankle brachial index, ultrasound, magnetic resonance, or computed
tomography imaging demonstrating stenosis in any peripheral artery; i.e., aorta, iliac, femoral,
popliteal, tibial, peroneal).
Exceptions:
None
Period of Assessment 1-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
Treatment of dyslipidemia reduces the risk of adverse cardiovascular events in patients with atherosclerosis. Cholesterol-lowering
therapy with an HMG coenzyme-A reductase inhibitor (statin) reduces the risk of myocardial infarction, stroke, and cardiovascular
death in patients with coronary artery disease. In the Heart Protection Study, statins reduced the risk of myocardial infarction, stroke,
or cardiovascular death by 24% in patients with PAD68. Despite the proven efficacy of effective lipid-lowering therapy in patients with
PAD, these patients are undertreated when compared to patients with coronary artery disease.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Treatment with a HMG coenzyme-A reductase inhibitor (statin) medication is indicated for all patients with PAD to achieve a target
LDL-C level of 100 mg/dL. (Level of Evidence: B)
Class IIa
Treatment with an HMG coenzyme-A reductase inhibitor (statin) medication to achieve a target LDL-C level of 70 mg/dL is
reasonable for patients with lower extremity PAD at very high risk of ischemic events. (Level of Evidence: B)
AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006
Update69
For lipid management:
Assess fasting lipid profile in all patients, and within 24 hr of hospitalization for those with an acute cardiovascular or coronary event.
For hospitalized patients, initiate lipid-lowering medication as recommended below before discharge according to the following
schedule:
● LDL-C should be 100 mg/dL (Class I, Level of Evidence: A), and
● Further reduction of LDL-C to 70 mg/dL is reasonable. (Class IIa, Level of Evidence: A)
● If baseline LDL-C is 100 mg/dL, initiate LDL-lowering drug therapy.† (Class I, Level of Evidence: A)
● If on-treatment LDL-C is 100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination‡).
(Class I, Level of Evidence: A).
Attribution/Aggregation
This measure should be reported by all primary care physicians or primary care practices and cardiovascular medicine physicians or
cardiovascular medicine practices. The level of “aggregation” (clinician versus practice) will depend upon the availability of adequate
sample sizes to provide stable estimates of performance.
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Per patient:
Whether patient
 Was prescribed a statin and had LDL-C 100 mg/dL OR
 Was prescribed a statin at maximal dose* OR
 Had LDL-C 100 mg/dL without a statin OR
 Had LDL-C 100 mg/dL and had a medical or patient reason that a statin at maximal dose* was not prescribed documented by a
physician, advanced practice nurse, or physician assistant.
Per patient population:
Percentage of all patients who
 Were prescribed a statin and had LDL-C 100 mg/dL OR
 Were prescribed a statin at maximal dose* OR
 Had LDL-C 100 mg/dL without a statin OR
 Had LDL-C 100 mg/dL and had a medical or patient reason that a statin at maximal dose* was not prescribed documented by a
physician, advanced practice nurse, or physician assistant.
Challenges to Implementation
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
LDL-C indicates low-density lipoprotein cholesterol; PAD, peripheral artery disease; and HMG, hydroxymethyl glutaryl.
*Maximal dosing for currently available statins:
 Atorvastatin80 mg/d
 Fluvastatin80 mg/d
 Lovastatin80 mg/d
 Pravastatin80 mg/d
 Rosuvastatin40 mg/d
 Simvastatin80 mg/d
†When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C 70 mg/dL is the chosen target, consider
drug titration to achieve this level, to minimize side effects and cost. When LDL-C 70 mg/dL is not achievable because of high baseline LDL-C levels, it
generally is possible to achieve reductions of 50% in LDL-C levels by either statins or LDL-C–lowering drug combinations.
‡Standard dose of statin with ezetimibe, bile acid sequestrate, or niacin.
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Smoking-cessation intervention for active smoking in patients with PAD
Numerator Patients identified as tobacco users who have received cessation intervention.
Cessation intervention may include smoking-cessation counseling (e.g., verbal advice to quit, referral
to smoking-cessation program or counselor) and/or pharmacologic therapy.* The type of intervention
should be explicitly captured.
Denominator All patients age 18 y at the start of the measurement period with PAD who are identified as tobacco
users.
PAD is defined as the presence of 1 or more of the following:
 Claudication
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
 Amputation for critical limb ischemia
 Abnormal noninvasive test (e.g., ankle brachial index, ultrasound, magnetic resonance, or computed
tomography imaging demonstrating stenosis in any peripheral artery; i.e., aorta, iliac, femoral,
popliteal, tibial, peroneal).
Exceptions:
None
Period of Assessment 2-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
Tobacco smoking is the most potent modifiable risk factor for development of PAD. Continued use of tobacco affects disease
progression and graft patency. Smoking status should be assessed at each encounter: patients should be strongly advised to quit, and
resources to assist in quitting should be offered.
(The 6 A factors should be included: ask, assess, advise, assure, arrange [a follow-up], and applaud).
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Individuals with lower extremity PAD who smoke cigarettes or use other forms of tobacco should be advised by each of their clinicians
to stop smoking and should be offered comprehensive smoking-cessation interventions, including behavior modification therapy,
nicotine replacement therapy, or bupropion. (Level of Evidence: B)*
Attribution/Aggregation
This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether the PAD patient identified as a tobacco user, received cessation intervention, and the type of cessation intervention that was
provided as documented in the medical records.
Per patient population:
Percentage of PAD patients identified as tobacco users who received cessation intervention and a breakdown of the type of cessation
intervention that was provided as documented in the medical record.
Challenges to Implementation
 Lack of documentation or consistency of description of interventions in medical record.
 Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
PAD indicates peripheral artery disease.
*Recent evidence supports the use of varenicline as an adjunct therapy for smoking cessation. For purposes of this measure, use of varenicline, nicotine
replacement therapy, or bupropion should all be considered pharmacologic therapy for smoking cessation.
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Antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or vascular death in patients with a history of
symptomatic PAD
Numerator Patients who were prescribed an antiplatelet agent (aspirin or clopidogrel)
Denominator All patients age 18 y with a history of symptomatic PAD.
History of symptomatic PAD is defined as the presence of the following:
 Claudication OR
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene) OR
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
OR
 Amputation for critical limb ischemia.
Exceptions:
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not
prescribing an antiplatelet agent (e.g., allergy or intolerance to both aspirin and clopidogrel, risk of
bleeding, noncompliance, use of warfarin, or other medical reason).
 Documentation of patient reason(s) for not prescribing an antiplatelet agent (e.g., patient refusal).
Period of Assessment 1-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
Administration of antiplatelet agents to patients with symptomatic atherosclerotic lower extremity PAD is well documented to reduce
the risk of myocardial infarction, stroke, or vascular death.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
1. Antiplatelet therapy is indicated to reduce the risk of myocardial infarction, stroke, or vascular death in individuals with
atherosclerotic lower extremity PAD. (Level of Evidence: A)
2. Aspirin, in daily doses of 75 to 325 mg, is recommended as safe and effective antiplatelet therapy to reduce the risk of myocardial
infarction, stroke, or
vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: A)
3. Clopidogrel (75 mg/d) is recommended as an effective alternative antiplatelet therapy to aspirin to reduce the risk of myocardial
infarction, stroke, or vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: B)
Attribution/Aggregation
This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether a patient with a history of symptomatic PAD was prescribed aspirin or clopidogrel.
Per patient population:
Percentage of all patients with a history of symptomatic PAD who were prescribed aspirin or clopidogrel.
Challenges to Implementation
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
PAD indicates peripheral artery disease.
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Supervised exercise training for patients with intermittent claudication
Numerator Patients who were
 Offered a supervised exercise training program as an option (preferred) OR
 Given explicit written or verbal instructions for unsupervised exercise (acceptable alternative if no
supervised program is accessible*) AND had a medical, patient, or system reason documented by a
physician, advanced practice nurse, or physician assistant that they could not be offered a supervised
program.
Note: Exercise training should be performed for a minimum of 30 to 45 min, at least 3 times/wk, for
a minimum of 12 wks.70
Denominator Patients age 18 y with intermittent claudication
Exceptions:
Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant that
patient was not offered a supervised exercise training program as an option, such as
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 Unstable angina or recent myocardial infarction
 Decompensated heart failure
 Uncontrolled cardiac arrhythmias
 Severe or symptomatic valvular disease
 Other conditions that could be aggravated by exercise including, but not limited to, severe joint
disease, uncontrolled diabetes, uncontrolled hypertension, or severe pulmonary disease.
Period of Assessment 1-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
A supervised claudication exercise program is known to result in an increase in the speed, distance, and duration walked in a high
fraction of candidates, with decreased claudication symptoms at each workload or distance. In addition, exercise programs achieve
significant systemic risk-reduction benefits (lowered blood pressure, improved glycemic control, and improved lipid profile). These
functional and biochemical benefits accrue gradually and become evident over 4 to 8 wks and increase progressively over 12 wks. The
biological mechanisms underlying the exercise improvements are complex, and there is inadequate evidence to attribute this functional
benefit, as is often believed, to the growth of new collaterals (angiogenesis). Although the mechanism(s) by which exercise improves
walking is unknown, studies have suggested that 1 or more of the following may play a role: alterations in skeletal muscle metabolism,
reduced inflammation, improvement in endothelial function and hemorheology, carnitine metabolism, or altered gait. Adverse events,
although possible, are rare, and the risk can be further reduced with appropriate medical screening before starting a program.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Individuals with intermittent claudication who are offered the option of endovascular or surgical therapies should be provided
information regarding supervised claudication exercise therapy and pharmacotherapy.
1. A program of supervised exercise training is recommended as an initial treatment modality for patients with intermittent claudication.
(Level of Evidence: A)
2. Supervised exercise training should be performed for a minimum of 30 to 45 minutes, in sessions performed at least 3 times per
week, for a minimum of
12 weeks. (Level of Evidence: A)
Class IIb
The usefulness of unsupervised exercise programs is not well established as an effective initial treatment modality for patients with
intermittent claudication. (Level of Evidence: B)
TASC-II40
Recommendation 14
Exercise therapy in intermittent claudication:
 Supervised exercise should be made available as part of the initial treatment for all patients with peripheral arterial disease [A].
 The most effective programs employ treadmill or track walking that is of sufficient intensity to bring on claudication, followed by
rest, over the course of a 30 to 60-min session. Exercise sessions are typically conducted 3 times a week for 3 months [A].
American College of Sports Medicine Guidelines for Exercise Testing and Prescription, 7th ed, 200671
Initial enrollment in a medically supervised program with ECG, heart rate, and BP monitoring is encouraged.
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This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether patient was offered the option of a supervised exercise program, if accessible, or given explicit instructions for an unsupervised
program if a supervised program is not accessible. Documentation should include whether a supervised exercise training program is
available in the local community.
Per patient population:
Percentage of patients who were offered the option of an exercise program either supervised, if accessible, or given explicit instructions
for an unsupervised program if a supervised program is not accessible. Documentation should include whether a supervised exercise
training program is available in the local community.
Challenges to Implementation
 Locating information in the medical record.
 Access to supervised exercise training records if the program is located at another facility.
 Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
*Inaccessible means that no program is available in the patient’s area, or is affordable by insurance or by pricing within the patient’s economic means, or will
accommodate the patient’s work hours or other fixed schedule barriers.72
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ABI and Duplex ultrasound of lower extremity vein bypass site
Numerator Patients who had an ABI and Duplex ultrasound of their infrainguinal vein bypass graft
revascularization site at least once during the 1-y measurement period.
Denominator All patients age 40 y who have undergone arterial bypass with autologous vein graft surgery for
infrainguinal revascularization.
Exceptions:
 Patients with synthetic bypass grafts
 Patients with medical reason(s) documented by a physician, advanced practice nurse, or physician
assistant for not performing ABI and Duplex ultrasound (e.g., patients who have undergone major
lower limb amputation remote from their revascularization procedure)
 Documented patient reason(s) that ABI and Duplex ultrasound could not be performed (e.g.,
patient refusal)
Period of Assessment 1-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record, vascular
laboratory data reports
Rationale
Infrainguinal venous bypass grafts are at risk for developing stenoses, which, if unrecognized, may result in graft thrombosis. Once
thrombosed, the secondary patency rates of these grafts are poor. Performing physical examination and ABI testing are insufficient
methods of determining whether a stenosis is present. Routine Duplex scan surveillance has been demonstrated to identify vein grafts at
risk for failure. Although there is some conflict in the literature, identification and revision of these grafts has been shown to improve
long-term results. Synthetic grafts may also develop stenoses; however, graft thrombosis is relatively easily managed with surgical
thrombectomy, and secondary patency rates are similar to those of primary assisted patency.
Similar data do not exist in infrainguinal endovascular intervention; however, if the revascularization was complex, and the
challenges of restoring patency after failure of the intervention are great, it is intuitive that surveillance in a manner similar to that of
infrainguinal venous bypass grafts be employed.
The durability of suprainguinal bypass grafts and endovascular interventions are superior to those of infrainguinal interventions, and
given the challenges of Duplex ultrasound surveillance in iliac arteries, routine surveillance is not recommended.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Long-term patency of infrainguinal bypass grafts should be evaluated in a surveillance program, which should include an interval
vascular history, resting ABIs, physical examination, and a Duplex ultrasound at regular intervals if a venous conduit has been used.
(Level of Evidence: B)
Duplex ultrasound is recommended for routine surveillance after femoral-popliteal and femoral-tibial-pedal bypass with a venous
conduit. Minimum surveillance intervals are approximately 3, 6, and 12 months, and then yearly after graft placement. (Level of
Evidence: A)
Attribution/Aggregation
This measure should be reported by vascular specialists or vascular specialist practices only. The level of “aggregation” (clinician versus
practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether ABI and Duplex ultrasound of the revascularization site was performed at least once during the measurement period.
Per patient population:
Percentage of patients for whom ABI and Duplex ultrasound of the revascularization site was performed at least once during the
measurement period.
Challenges to Implementation
 This requires a vascular laboratory skilled in performance of lower extremity arterial Duplex ultrasonography, as well as having a
method to schedule surveillance testing of patients with infrainguinal lower extremity revascularization.
 Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
ABI indicates ankle-brachial index.
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Monitoring of asymptomatic AAA between 4.0 and 5.4 cm in diameter
Numerator Patients whose AAA diameter was measured at least once within the last year.
Denominator All patients age 18 y and over with asymptomatic abdominal aortic aneurysm between 4.0 and 5.4
cm at the start of the measurement period.
Exceptions:
 Patients with known symptomatic AAA
 Patients with AAA diameter 4.0 cm or 5.5 cm
 Patients who have had elective repair of their AAA
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant, for
not measuring AAA diameter, for example: Patients who are not candidates for AAA repair of any
type due to comorbidities or surgical risk (e.g., metastatic cancer, dementia, severe cardiopulmonary
disease).
 Documented patient reason(s) for not measuring AAA diameter (e.g., patient refusal).
Period of Assessment 1-y measurement period
Sources of Data Electronic medical records, retrospective paper records, and prospective flow sheets
Rationale
Aneurysm size remains the single most important predictor not only for aneurysm rupture but also for death from other cardiovascular
events. Prospective studies have indicated that small aneurysms (5.5 cm) have a low risk of rupture and may be safely monitored with
annual or semiannual imaging.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
1. Patients with infrarenal or juxtarenal AAAs measuring 5.5 cm or larger should undergo repair to eliminate the risk of rupture. (Level
of Evidence: B)
2. Patients with infrarenal or juxtarenal AAAs measuring 4.0 to 5.4 cm should be monitored by ultrasound, computerized tomography
imaging, or magnetic resonance every 6 to 12 months to detect expansion. (Level of Evidence: A)
Attribution/Aggregation
This measure should be reported by all clinicians and/or practices managing patients with cardiovascular disease. The level of
“aggregation” clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of
performance.
Method of Reporting
Per patient:
Whether the patient’s abdominal aortic aneurysm diameter was measured.
Per patient population:
Percentage of patients whose abdominal aortic aneurysm diameter was measured.
Challenges to Implementation
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
AAA indicates abdominal aortic aneurysms.
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Medical or personal history of walking impairment, claudication, or ischemic rest pain and nonhealing wounds in patients at
risk for lower extremity PAD
Numerator All patients for whom a vascular review of systems is documented at least once in the last 2 years.
Vascular review of systems must include assessment of ALL of the following:
 Walking impairment or claudication
 Ischemic rest pain
 Lower extremity nonhealing wounds
Denominator All patients age 18 y who are “at risk” for PAD.
At risk is defined as the presence of 1 or more of the following:
 Age 50 y, with diabetes and 1 or more other atherosclerosis risk factors (smoking, dyslipidemia,
hypertension, or hyperhomocysteinemia);
 Age 50–69 y, with a history of smoking or diabetes;
 Age 70 y;
 Known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
Exceptions:
None
Period of Assessment 2-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
There is a high prevalence (about 30%) of PAD in this “at risk” population. Because the symptoms of PAD may be confused with
arthritis, or simply aging, it is advisable to specifically ask about symptoms of claudication or critical limb ischemia.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Individuals at risk for lower extremity PAD (see Section 2.1.1, Table 2) should undergo a vascular review of symptoms to assess
walking impairment, claudication, ischemic rest pain, and/or the presence of nonhealing wounds. (Level of Evidence: C)
Table 2 (Section 2.1.1) Individuals at Risk for Lower Extremity Peripheral Arterial Disease:
 Age 50 y, with diabetes and one other atherosclerosis risk factor (smoking, dyslipidemia, hypertension, or hyperhomocysteinemia)
 Age 50–69 y and history of smoking or diabetes
 Age 70 y
 Leg symptoms with exertion (suggestive of claudication) or ischemic rest pain
 Abnormal lower extremity pulse examination
 Known atherosclerotic coronary, carotid, or renal artery disease
A history of walking impairment, claudication, ischemic rest pain, and/or nonhealing wounds is recommended as a required component of a
standard ROS for adults age50 y who have atherosclerosis risk factors and for adults age70 y. (Level of Evidence: C)
TASC-II
Recommendation 1.140
History and physical examination in suspected PAD:
● Individuals with risk factors for PAD, limb symptoms on exertion, or reduced limb function should undergo a vascular history to
evaluate for symptoms of claudication or other limb symptoms that limit walking ability [B].
Attribution/Aggregation
This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend on the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether a vascular review of systems was recorded.
Per patient population:
Percentage of all patients who had a vascular review of systems recorded.
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 Identifying the population “at risk” for PAD.
 Sample sizes may preclude reporting of reliable performance estimates, particularly at the clinician level.
PAD indicates peripheral artery disease.
*This measure has been designated for use in internal quality improvement programs only. It is not appropriate for any other use (e.g., pay for performance,
physician ranking, or public reporting programs).
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Measurement of pulses in the lower extremities in patients at risk for PAD
Numerator Patients in whom a lower extremity pulse examination was documented at least once in the last 2 years.
The pulse examination should include the femoral, popliteal, dorsalis pedis, and posterior tibial pulses.
Denominator All patients age 18 y who are “at risk” for PAD.
At risk is defined as the presence of 1 or more of the following:
 Age 50 y, with diabetes and 1 or more other atherosclerosis risk factors (smoking, dyslipidemia,
hypertension, or hyperhomocysteinemia);
 Age 50–69 y, with a history of smoking or diabetes;
 Age 70 y;
 Walking impairment or claudication, ischemic rest pain, or lower extremity nonhealing wounds
 Known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
Exceptions:
Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not
performing a lower extremity pulse examination (e.g., amputation).
Period of Assessment 2-y measurement period
Sources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
Examination of the pulses is important to document the presence of peripheral artery disease, determine the location of obstruction,
and detect the presence of aneurysms.
Clinical Recommendation(s)
ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease12
Class I
Individuals at risk for lower extremity PAD (see Section 2.1.1, Table 2, of the full-text guidelines) should undergo comprehensive pulse
examination and inspection of the feet. (Level of Evidence: C)
Table 2 (Section 2.1.1) Individuals at Risk for Lower Extremity Peripheral Arterial Disease:
 Age 50 y, with diabetes and 1 other atherosclerosis risk factor (smoking, dyslipidemia, hypertension, or hyperhomocysteinemia)
 Age 50–69 y and history of smoking or diabetes
 Age 70 y
 Leg symptoms with exertion (suggestive of claudication) or ischemic rest pain
 Abnormal lower extremity pulse examination
 Known atherosclerotic coronary, carotid, or renal artery disease
TASC-II
Recommendation 1.140
History and physical examination in suspected PAD:
● Patients at risk for PAD or patients with reduced limb function should also have a vascular examination evaluating peripheral pulses [B].
Attribution/Aggregation
This measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation”
(clinician versus practice) will depend on the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
Per patient:
Whether a lower extremity pulse examination was performed.
Per patient population:
Percentage of patients for whom a lower extremity pulse examination was performed.
Challenges to Implementation
Identifying the population “at risk” for PAD.
Sample sizes may preclude reporting of reliable performance estimates, particularly at the clinician level.
PAD indicates peripheral artery disease.
*This measure has been designated for use in internal quality improvement programs only. It is not appropriate for any other use (e.g., pay for performance,
physician ranking, or public reporting programs).
Appendix D. Sample Performance Measure Survey Form and Exclusion Criteria Definitions
SAMPLE SURVEY FORM
PERFORMANCE MEASURE SURVEY
Please see the definition for each of the criteria below in the attached Performance Measure Survey Guide.
Indicate your selection by marking X in the appropriate field
ACC/AHA PAD
GUIDELINE
RECOMMENDATIONS
A.
Insufficient
evidence
B.
Uninterpretable
C.
Not
actionable
D.
Unclear
patient
population
E.
Not
clinically
meaningful
F.
Uncertain
reliability
across
settings
G.
Uncertain
feasibility
due to
data
collection
effort
H.
Uncertain
feasibility
due to
cost of
data
collection
I.
Uncertain
data
collection
period
Other,
specify
Potential
measure?
Y/N/Other Comment
Recommendation from
guideline to be
considered as
potential measure*
ABI indicates ankle-brachial index; PAD, peripheral artery disease.
*Example: The resting ABI should be used to establish the lower extremity PAD diagnosis in patients with suspected lower extremity PAD, defined as individuals with exertional leg symptoms, with nonhealing wounds,
who are age 70 or who are age 50 y with a history of smoking or diabetes. (Level of Evidence: C).
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Potential Challenge to Implementation Considerations
Useful in Improving Patient Outcomes
1. Insufficient evidence: The scientific basis for the
recommendation is not well established.
Considering level of evidence, mark this as a potential
challenge to implementation if you believe it is
inappropriate to consider as a potential performance
measure.
2. Not interpretable: The results of the (potential) measure are
not interpretable by practitioners
This is your assessment of the degree to which a
provider can clearly understand what the results of a
measure based on this recommendation mean and can
take action if necessary.
3. Not actionable: The recommendation addresses an area that is
not under the practitioner’s control.
This is your assessment of the degree to which a
provider is empowered and can influence the activities
of the healthcare system toward improvement.
Measure Design
4. Unclear patient population This is your assessment of whether the patient group to
whom this recommendation applies (denominator)
can be explicitly defined using criteria that are
clinically meaningful.
5. Not clinically meaningful The recommendation does not capture clinically
meaningful aspects of care.
6. Uncertain reliability across settings The recommendation is not likely to be applicable across
organizations and delivery settings.
Measure Implementation
7. Uncertain feasibility due to data collection effort: The data
required to measure successful implementation of
recommendation cannot be obtained with reasonable effort.
From your perspective, the required data can be typically
abstracted from patient charts or there are national
registries or other databases readily available.
8. Uncertain feasibility due to cost of data collection: The data
required to measure successful implementation of
recommendation cannot be obtained at reasonable cost.
9. Uncertain data collection period: The data required to
measure successful implementation of recommendation cannot
be obtained within the period allowed for data collection.
Overall Assessment
10. Overall assessment: Considering your assessment of this
recommendation on all dimensions above, rate this
recommendation for inclusion in the ACCF/AHA/ACR/
SCAI/SIR/SVM/SVN/SVS PAD Performance Measure set.
Consider a balance in the continuum of care. Consider
overall purpose of the measurement set and the
intended user.
On the survey form enter:
YES: This recommendation should be considered for
further development into a performance measure and
inclusion in the
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS
PAD Performance Measure set.
NO: This recommendation should not be considered
for further development into a performance measure
or inclusion in the ACCF/AHA/ACR/SCAI/SIR/
SVM/SVN/SVS PAD Performance Measure set.
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ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS Peripheral Artery Disease Performance Measurement Set
Visit Date: ______ /______ /______ Physician Evaluating Patient: ____________________________
1. Demographics/Patient Information
Patient Last Name:
________________________
Patient First Name:
________________________
Patient Middle Name/Initial:
_________________
Sex: e Malee Female Date of Birth: ____ /____ /____ Age: _________ years
2. History/Diagnoses (Check all that apply)
e Peripheral Artery Disease (PAD) e Claudication e Optional: Hyperhomocysteinemia
e Diabetes e Walking Impairment e Optional: Hypertension
e Atherosclerosis other than PAD (coronary,
carotid, or renal artery disease)
e Lower Extremity Nonhealing Wounds e Optional: Dyslipidemia
e Critical limb ischemia (ischemic rest
pain, nonhealing ischemic ulcers,
gangrene)
e Optional: Ischemic Rest Pain
e Infrainguinal vein bypass graft revascularization
¡ If yes, and patient is age 40 y, also complete section 7 below
Abdominal Aortic Aneurysm (AAA): e Yes e No
¡ Complete if patient has a history of AAA: e Elective repair of AAA performed
¡ Complete if no elective repair has been performed: Most recent AAA diameter: ___cm Date diameter measured: __ /__ /__
¡ Complete if AAA diameter not measured:
Medical or patient reason(s) AAA diameter was not measured (MD, DO, APN or PA only): _________________
Tobacco Use: e Never smoked e Former smoker: Date Quit: ____ /_____ (month, if known/year) e Current Smoker
¡ Complete if patient is a current smoker:
e Advised to quit smoking e Referred for smoking-cessation counseling e Medication prescribed: _________
(e.g., bupropion, varenicline, nicotine patches,
gum, or lozenges)
e Other ______________
3. Laboratory Assessments
LDL-Cholesterol ________mg/dL
4. Medications (Current and Prescribed)
Medication Allergy/Intolerance: e Aspirin e Clopidogrel e Statin Medications
Medication Category PrescribedYes No
A Aspirin e e ¡ Complete if neither aspirin nor clopidogrel prescribed:
Clopidogrel e e Medical or patient reason(s) neither aspirin nor
clopidogrel prescribed
(MD, DO, APN, or PA only): ______
B Statin Medication e e ¡ If Yes,
enter name,
dosage, and
frequency of
statin
medication
Statin
Name
Statin
Dosage
Statin
Frequency
¡ Complete if no statin medication prescribed:
Medical or patient reason(s) statin not prescribed or reason statin could not be prescribed at maximal dosage*
(MD, DO, APN, or PA only): _____________
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5. Optional: Lower Extremity Pulse Examination
Complete if patient is:
□ Age 50 y, with a history of diabetes and 1 or more of the following: smoking, dyslipidemia, hypertension, or hyperhomocysteinemia
OR
□ Age 50–69 y, with a history of smoking or diabetes
OR
□ Age 70 y
OR
□ Has a history of walking impairment or claudication, ischemic rest pain, or lower extremity nonhealing wounds
OR
□ Has known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
Pulse location Pulse examination
performed
¡ If yes, record Narrative or Numeric Assessment (e.g., present or
absent, or graded on scale [0  absent, 1diminished, 2normal,
3bounding])Yes No
Femoral e e
Popliteal e e
Dorsalis pedis e e
Posterior tibial e e
¡ Complete if any of the pulses above was not examined:
Medical reason(s) for not performing lower extremity pulse examination (MD, DO, APN, or PA only): _______
6. Ankle Brachial Index
Complete if patient is:
□ Age  18 y, with a history of walking impairment or claudication or lower extremity nonhealing wounds
OR
□ Age 50–69 y, with a history diabetes or smoking
OR
□ Age 70 y
Ankle Brachial Index (ABI) performed ¡ If yes, enter ¡ Complete if no ABI performed:
e Yes e No Numerical result:
(R) ________
(L) ________
Medical reason(s) for not performing an ABI (MD, DO, APN, or PA
only):___________________________________
7. Other Diagnostic Tests (Revascularization Surveillance)
Complete if patient is age 40 y and has history of infrainguinal vein bypass graft revascularization or infrainguinal endovascular revascularization. (Optional for
endovascular revascularization)
Duplex ultrasound of revascularization site performed ¡ Complete if no Duplex ultrasound performed:
e Yes e No Medical or patient reason(s) for not performing Duplex ultrasound of revascularization
site (MD, DO, APN, or PA only): _______
ABI of revascularization site performed ¡ Complete if no ABI performed:
e Yes e No Medical or patient reason(s) for not performing ABI of revascularization site (MD, DO,
APN, or PA only):______
8. Therapeutic Recommendations
Complete if patient has a history of claudication
Patient offered a supervised exercise training program Yes No
e e
¡ Complete if no supervised exercise program is accessible: e e
Patient given explicit written or verbal instruction for unsupervised exercise
¡ Complete if only written or verbal instructions given:
Reason supervised exercise program could not be offered: ______________________
¡ Complete if patient was not offered a supervised exercise training program or given explicit written or verbal instructions for unsupervised exercise:
Medical reason(s) patient was not offered a supervised exercise training program or given explicit written or verbal instructions for unsupervised exercise (MD, DO,
APN or PA only): __________________
*Maximal dosing for currently available statins:
Atorvastatin 80 mg/d Pravastatin 80 mg/d
Fluvastatin 80 mg/d Rosuvastatin40 mg/d
Lovastatin 80 mg/d Simvastatin 80 mg/d
